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Fatigue, Sleep Disturbances, and Their
Inﬂuence on Quality of Life in Cervical
Dystonia Patients
Marenka Smit, MD,1 Arwen S. J. Kamphuis, BSc,1 Anna L. Bartels, MD, PhD,1,2 Vladimir Han, MD,3,4 Roy E. Stewart, PhD,5 Inge Zijdewind,
PhD,6 Marina A. Tijssen, MD, PhD1,*
Abstract: Background: Nonmotor symptoms (NMS) are highly prevalent in cervical dystonia (CD). In general,
fatigue and sleep are important NMS that determine a decreased health-related quality of life (HR-QoL), but
their inﬂuence in CD is unknown. The authors systematically investigated fatigue, excessive daytime
sleepiness (EDS), and sleep quality in patients with CD and controls and assessed the inﬂuence of
psychiatric comorbidity, pain, and dystonia motor severity. They also examined the predictors of HR-QoL.
Methods: The study included 44 patients with CD and 43 matched controls. Fatigue, EDS, and sleep quality
were assessed with quantitative questionnaires and corrected for depression and anxiety using analysis of
covariance. The Toronto Western Spasmodic Torticollis Rating Scale and the Clinical Global Impression Scale-
jerks/tremor subscale were used to score motor severity and to assess whether motor characteristics could
explain an additional part of the variation in fatigue and sleep-related measures. HR-QoL was determined
with the RAND-36 item Health Survey, and predictors of HR-QoL were assessed using multiple regression.
Results: Fatigue scores were increased independently from psychiatric comorbidity (4.0 vs. 2.7; P < 0.01),
whereas EDS (7.3 vs. 7.4; P = 0.95) and sleep quality (6.5 vs. 6.1; P = 0.73) were highly associated with
depression and anxiety. In patients with CD, motor severity did not explain the variations in fatigue (change in
the correlation coefﬁcient [DR2] = 0.06; P = 0.15), EDS (DR2 = 0.00; P = 0.96), or sleep quality (DR2 = 0.04;
P = 0.38) scores. Fatigue, EDS, psychiatric comorbidity, and pain predicted a decreased QoL.
Conclusion: Independent from psychiatric comorbidity and motor severity, fatigue appeared to be a primary
NMS. Sleep-related measures were highly associated with psychiatric comorbidity, but not with motor
severity. Only NMS predicted HR-QoL, which emphasizes the importance of attention to NMS in patients with
CD.
Introduction
Cervical dystonia (CD) is a hyperkinetic movement disorder
characterized by sustained or intermittent contractions of the
cervical musculature, leading to abnormal head postures.
Although CD is by its motor symptoms, growing evidence
indicates that nonmotor symptoms (NMS) are an important part
of the phenotype of CD1–3 and that they have a profound effect
on health-related quality of life (HR-QoL).3–5
Although psychiatric comorbidity has been studied more
extensively, only a few studies have investigated the prevalence
and severity of fatigue, excessive daytime sleepiness, and sleep
quality in patients with CD. Fatigue, which refers to an
increased level of perceived fatigue,6 has been described in 50%
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of patients with CD.7,8 Daytime sleepiness scale scores, as
reviewed by Hertenstein et al., are usually within the normal
range in patients with CD, whereas sleep quality reportedly was
reduced in several studies.3 To date, it is still unknown whether
these symptoms may be a response to or related with psychiatric
comorbidity or whether they are a secondary phenomenon in
response to motor symptoms. Interestingly, symptoms of exces-
sive daytime sleepiness and disturbed sleep quality did not
improve after botulinum toxin (BoNT) therapy a despite signif-
icant improvement of dystonia motor severity,9 suggesting that
these symptoms may be a primary phenomenon in dystonia.
Although the former studies have shown that fatigue and
sleep disturbances are highly prevalent in patients with CD,
methodological limitations were noted. Either an appropriate
control group or an objective CD motor score were lacking.
Moreover, not all studies examined the influence of depression,
anxiety, pain, and severity of motor symptoms on fatigue,
excessive daytime sleepiness, and sleep quality scores. HR-QoL
and the most important predictors of a reduced HR-QoL were
often not systematically assessed.
In the current study, we examined the prevalence and sever-
ity of fatigue, excessive daytime sleepiness, and sleep quality in
patients who had CD compared with a group of matched con-
trols. In addition, we calculated the fatigue and sleep-related
scores corrected for depression and anxiety. Then, in the patient
group, we used a stepwise linear regression model to examine
whether motor characteristics could explain an additional part
in the variation in fatigue and sleep-related measures other than
the known association with psychiatric comorbidity and pain.
In addition, we assessed which motor symptoms and/or NMS
were the most important contributors to a decreased HR-QoL.
Patients and Methods
Participants
We included patients who had clinically diagnosed, idiopathic
CD with a group of age-matched and sex-matched controls. An
exclusion criterion for the patients was the onset of CD before
age 18 years. Additional exclusion criteria for all participants
included other relevant neurological comorbidity and the use of
antidepressant medication. All participants had previously been
included in a study about psychiatric comorbidity (see also Smit
et al.10). Informed consent was obtained from all participants,
and the study was approved by the local ethics committee.
Fatigue, Excessive Daytime
Sleepiness, Sleep Quality, and
HR-QoL
Fatigue was evaluated using the Fatigue Severity Scale (FSS).
The FSS quantifies the impact of fatigue and contains 7 items,
which are scored on a scale from 1 to 9. The summed score
(maximum, 63) is divided by 9, and a total score of more than
4 is regarded as an indicator of fatigue.11 Excessive daytime
sleepiness was assessed using the self-administered Epworth
Sleepiness Scale (ESS), in which a score of 10 or higher (range,
0–24) indicates excessive daytime sleepiness.12 Quality of sleep
was evaluated using the Pittsburgh Sleep Quality Index (PSQI),
in which a score of 5 or higher (range, 0–21) indicates impaired
sleep quality.13 The severity of depression and anxiety were
measured with the Beck Depression Inventory (BDI)14 and the
Beck Anxiety Inventory (BAI),15 respectively. HR-QoL was
assessed using RAND-36 item Health Survey (RAND-36).16
For all scales, a score of zero indicates no complaints, and
increasing scores indicate increasing severity.
Motor Assessment
Motor assessment was performed by using a systematic video
protocol. To obtain the least influenced motor score, 39
patients were videotaped 2 weeks before their next BoNT
injections, and 5 patients were videotaped in the first week after
BoNT injections. CD severity was scored using the Toronto
Western Spasmodic Torticollis Rating Scale (TWSTRS).17
Because the TWSTRS does not include severity of jerks and
tremor, jerks and tremor also were scored using the 7-point
Clinical Global Impression Scale: CGI-S jerks-tremor.18 Motor
function was independently scored by 2 experts (M.S. and
V.H.) and revealed good agreement (>0.80 intraclass correlation
coefficients, 2-way mixed, absolute agreement, average mea-
sures). The average score of the 2 experts was used in the statis-
tical analysis.
Statistical Analysis
Statistical analyses were performed using the PASW Statistics 22
software package (SPSS Statistics; IBM Corporation, Armonk,
NY), and differences were considered significant at P < 0.05.
Demographic and clinical data were compared between patients
with CD and controls using the Pearson v2 test/Fisher exact
test or the Mann-Whitney U test. An analysis of covariance
(ANCOVA) was performed to control for the potential con-
founding effect of depression and anxiety on the FSS, ESS, and
PSQI. For this purpose, the BDI and BAI scores were com-
bined into 1 factor using factor analysis.
In the group of patients with CD, the influence of motor
severity on fatigue, excessive daytime sleepiness, and sleep
quality was assessed with a stepwise multiple linear regression
analysis. In the first step, we assessed the influence of depres-
sion, anxiety, and the severity of pain on the FSS, ESS, and
PSQI. In the second step, we assessed whether motor charac-
teristics, including dystonia, jerks, and tremor, could explain
an additional part of the variation in FSS, ESS, and PSQI
scores.
The influence of clinical variables on HR-QoL in patients
with CD was first assessed in a univariate analysis. Because we
had a relatively small number of patients, this was performed
with the Spearman’s q test, or, for the discrete dichotomous
variables, with the Pearson r test. In multiple regression analysis,
we then determined the influence of variables that had P values
<0.05 in the univariate analysis on the HR-QoL domains using
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This study included 44 patients with CD (mean age,
51 years; range, 20–80 years) and 43 controls (mean age,
54 years; range, 25–83 years) (Table 1). Nine patients with
CD used benzodiazepines, 1 used trihexyphenidyl, 1 used
gabapentin, and 1 used pregabalin. In the control group, 3
participants used benzodiazepines. Benzodiazepine type,
dosage, and frequency were highly variable. Mean ESS scores
(standard deviation) in patients with CD were significantly
higher in those who were using psychoactive medication
(mean  standard deviation, 12.6  6.7 vs. 7.7  6.6;
P = 0.04), but no relation with sleep quality was observed (
Table S1). None of the participants were officially diagnosed
with restless legs syndrome (RLS). Snoring was significantly
more prevalent in patients with CD versus controls (68.2%
vs. 39.5%; P < 0.01). Breath-holding spells also were more
prevalent in CD patients, although the difference was not
significant (18.2% vs. 7.0%, respectively; P = 0.12).
Patients with CD had a mean  standard deviation dystonia
duration of 13.3  11.2 years. The mean  standard deviation
total TWSTRS score was 34.1  13.0, and the mean CGI-S
jerks/tremor score was 2.5  1.3. Patients scored significantly
worse than controls on the FSS (4.4  1.7 vs. 2.7  1.4;
P < 0.01), the ESS (8.8  6.9 vs. 5.8  4.9; P = 0.04), and
the PSQI (7.4  3.9 vs. 5.1  4.4; P < 0.01). In addition,
patients scored significantly worse on the depression rating scale
(10.6  7.3 vs. 4.5  5.0; P < 0.01) and the anxiety rating
scale (9.3  6.8 vs. 4.0  4.2; P < 0.01).
Based on the criteria described above (see Patients and Meth-
ods), significantly more patients fulfilled the criteria for fatigue
(n = 28 [63.3%] vs. 7 [16.7%]; P < 0.01), excessive daytime
sleepiness (n = 19 [43.2%] vs. 9 [20.9%]; P = 0.03) and
impaired sleep quality (n = 34 [77.3%] vs. 18 [41.9%];
P < 0.01) compared with controls.
After controlling for depression and anxiety, patients still
scored significantly worse on the FSS (mean score, 4.0 vs. 3.1;
P = 0.01). In contrast, scores on the ESS (mean score, 7.3 vs.
7.4; P = 0.95) and the PSQI (mean score, 6.5 vs. 6.1;
P = 0.73) were not significantly different between groups after
controlling for depression and anxiety (Table 1).
Predictors of Fatigue, Excessive
Daytime Sleepiness, and Sleep
Disturbances
+To assess whether the FSS, ESS, and PSQI scores in the CD
patient group were associated with the severity of the dystonic
posturing, jerks, and/or tremor, we performed a stepwise linear
regression analysis. In the first step, we assessed the influence of
depression, anxiety, and the severity of pain on FSS, ESS, and
PSQI scores. In the second step, we assessed the influence of
the severity of dystonia, jerks, and tremor in addition to Step 1.
Thus, in the first step, we included factors that are known from
the literature to have an effect on fatigue and sleep-related mea-
sures; and, in the second step, we assessed whether motor char-
acteristics could explain an additional part of the variation in
fatigue and sleep-related measures.
The FSS was significantly influenced by depression, anxiety,
and pain (correlation coefficient [R2] = 0.37 for Step 1;
P < 0.01), with a significant influence from depressive symp-
toms (b = 0.44; P = 0.01) (Table 2, S2). Motor severity did
not influence fatigue scores (change in the correlation
TABLE 1 Clinical Characteristics
Characteristic Mean  SD P value
CD, n = 44 HC, n = 43
Age, y 54  10.6 54  11.3 0.93
Sex: No. of men/women 12/32 11/32 0.86
Motor characteristics
Duration of dystonia, years 13.3  11.2
TWSTRS score
Total 34.1  13.0
Severity 16.0  4.6
Disability 10.2  5.5
Pain 7.9  6.2
CGI-S jerks/tremor 2.5  1.3
Nonmotor characteristics
BDI score 10.6  7.3 4.5  5.0 <0.01
BAI score 9.3  6.8 4.0  4.2 <0.01
Uncorrected/corrected scores: Mean  SD/meana
FSS 4.4  1.7/4.0 2.7  1.4/3.1 <0.01/0.01
ESS 8.8  6.9/7.3 5.8  4.9/7.4 0.04/0.95
PSQI 7.4  3.9/6.5 5.1  4.4/6.1 <0.01/0.73
CD, cervical dystonia; HC, health controls; SD, standard deviation; TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale; CGI-S, Clini-
cal Global Impression Scale; BDI, Beck Depression Inventory; BAI, Beck Anxiety Inventory; FSS, Fatigue Severity Scale; ESS, Epsworth Sleepi-
ness Scale; PSQI, Pittsburgh Sleep Quality Index.
aCorrected values are controlled for depression and anxiety as 1 factor by using analysis of covariance.
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coefficient [DR2] = 0.06 for Step 2; P = 0.15), although the
CGI-S jerks/tremor score showed a mild association with the
FSS (b = 0.27; P = 0.05).
The ESS was also significantly influenced by Step 1
(R2 = 0.31 for Step 1; P < 0.01), with depression being the
only significant predictor (b = 0.57; P < 0.01). In Step 2,
severity of dystonia, jerks, and tremor did not significantly
influence the model (DR2 = 0.00 for Step 2; P = 0.96).
The PSQI was significantly influenced by the TWSTRS pain
score (b = 0.40; P = 0.01; R2 = 0.26 for Step 1; P = 0.01),
whereas depressive symptoms had no significant influence.
Motor symptoms did not influence the PSQI score
(DR2 = 0.04 for Step 2; P = 0.38).
HR-QoL and Predictors of a
Decreased HR-QoL
The patient group scored significantly worse on the first 8
domains of the HR-QoL rating scale compared with the
healthy control group (Table 3). Univariate analysis showed that
decreased HR-QoL in patients with CD was associated with
fatigue, excessive daytime sleepiness, sleep disturbances, depres-
sion, anxiety, and pain, whereas motor symptoms were not
associated with HR-QoL (Table 4).
Multiple linear regression analysis revealed that the FSS had a
significant negative influence on the domains physical function-
ing (b = 0.60; P < 0.01), mental health (b = 0.26;
TABLE 2 Inﬂuence of Motor Symptom Severity on the Fatigue
Severity Scale, the Epsworth Sleepiness Scale, and the Pittsburgh
Sleep Quality Index*
Step 1 Step 2
Measure R2 P value DR2 P value
FSS 0.37 <0.01 0.06 0.15
ESS 0.31 <0.01 0.00 0.96
PSQI 0.26 0.01 0.04 0.38
DR2, change in the correlation coefﬁcient; FSS, Fatigue Severity
Scale; ESS, Epsworth Sleepiness Scale; PSQI, Pittsburgh Sleep
Quality Index; R2, correlation coefﬁcient.
*Multiple linear regression analysis was used to predict the effect
of depression, anxiety, and pain (Step 1) on the FSS, ESS, and PSQI
and the additional effect of severity of motor symptoms (Step 2) in
patients with cervical dystonia.
TABLE 3 Health-related Quality of Life in Patients with Cervical Dystonia and Healthy Controls
Median (Interquartile Range) P value
HR-QoL Domain CD, n = 44 HC, n = 43
Physical functioning 75.0 (55.0–90.0) 95.0 (90.0–100.0) <0.01
Social functioning 75.0 (62.5–88.0) 100.0 (88.0–100.0) <0.01
Role limitation-physical 50.0 (0.0–100.0) 100.0 (75.0–100.0) <0.01
Role limitation-emotional 100.0 (42.4–100.0) 100.0 (100.0–100.0)
Mental health 72.0 (63.5–80.0) 88.0 (80.0–92.0) <0.01
Vitality 55.0 (40.0–68.8) 80.0 (65.0–85.0) <0.01
Pain 62.0 (45.0–79.9) 90.0 (67.0–100.0) <0.01
General health perception 57.5 (41.3–70.0) 80.0 (70.0–90.0) <0.01
Expected health change 50.0 (31.3–50.0) 50.0 (50.0–50.0) 0.13
HR-QoL, health-related quality of life; CD, cervical dystonia; HC, healthy controls.
TABLE 4 Correlations between the Domains of Health-related Quality of Life and Clinical Variables in Patients with Cervical Dystonia
Correlation Coefﬁcient
Variable PF SF RLP RLE MH Vitality Pain GHP EHC
Demographic characteristics
Age 0.14 0.22 0.36a 0.19 0.29 0.38b 0.19 0.06 0.05
Sex 0.03 0.19 0.06 0.11 0.13 0.03 0.06 0.03 0.13
Nonmotor scores
FSS 0.71b 0.54b 0.55b 0.37a 0.37a 0.57b 0.52b 0.46b 0.15
ESS 0.55b 0.61b 0.42b 0.24 0.54b 0.57b 0.28 0.35a 0.11
PSQI 0.29 0.33a 0.33a 0.14 0.32a 0.28 0.35a 0.36a 0.08
BDI 0.51b 0.62b 0.41b 0.61b 0.69b 0.65b 0.44b 0.44b 0.02
BAI 0.43b 0.16 0.31a 0.51b 0.70b 0.58b 0.42b 0.48b 0.02
Dystonia rating scales
Dystonia duration 0.09 0.03 0.04 0.20 0.04 0.07 0.11 0.06 0.32a
TWSTRS severity 0.13 0.17 0.11 0.12 0.08 0.08 0.10 0.08 0.01
TWSTRS pain 0.44b 0.20 0.41b 0.38a 0.24 0.37a 0.61b 0.36a 0.13
CGIS jerks/tremor 0.01 0.21 0.06 0.19 0.10 0.04 0.02 0.17 0.08
PF, physical functioning; SF, social functioning; RLP, role limitation-physical; RLE, role limitation-emotional; MH, mental health; GHP, general
health perception; EHC, expected health change; FSS, Fatigue Severity Scale; ESS, Epsworth Sleepiness Scale; PSQI, Pittsburgh Sleep Quality
Index; BDI, Beck Depression Inventory; BAI, Beck Anxiety Inventory; TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale; CGI-S, Clini-
cal Global Impression Scale.
aP < 0.05; bP < 0.01.
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P = 0.03) and pain (b = 0.37; P < 0.01) (Table 5). The ESS
had a significant negative influence on the domains mental
health (b = 0.39; P < 0.01) and vitality (b = 0.36;
P = 0.01). The PSQI was not associated with any of the HR-
QoL domains. In addition to fatigue and excessive daytime
sleepiness, the severity of depression, anxiety, and pain was also
negatively associated with the domains physical functioning,
social functioning, role limitation-emotional, vitality, and pain.
Motor symptoms were not included in the multiple regression
analysis, because they were not associated with HR-QoL in the
univariate analysis.
Discussion
These results demonstrate a significantly increased prevalence of
fatigue, excessive daytime sleepiness, and impaired sleep quality
in patients who have CD compared with controls. The level of
perceived fatigue in patients with CD appeared to be increase
independent of psychiatric comorbidity and motor symptom
severity. Excessive daytime sleepiness and sleep quality were
highly associated with depression and anxiety, but not with
motor symptoms severity.
Compared with other studies, we observed a higher preva-
lence of fatigue in patients with CD. In our cohort, 63.3% ful-
filled the criteria of fatigue, whereas 2 other studies reported a
prevalence of 50%.7,8 One explanation could be that depressive
symptom scores were also higher in our cohort compared with
those in the study by Wagle Shukla et al. (10.6 vs. 6.8).7
Because depression is positively associated with fatigue scores,
this might explain the higher frequency of fatigue in our patient
group. However, after correction for depression and anxiety,
fatigue scores were still significantly increased in our CD popu-
lation. Moreover, we also observed higher excessive daytime
sleepiness scores (8.8 vs. 7.4), a variable that is also positively
associated with fatigue. Severity of motor symptoms did not sig-
nificantly influence fatigue scores, although severity of jerks/tre-
mor showed a mild association with the perceived level of
fatigue. Similar to other neurological disorders like Parkinson’s
disease (PD) and multiple sclerosis, in which fatigue is a primary
NMS,6 fatigue may be part of the phenotype of dystonia instead
of a secondary phenomenon. Dysfunction of the basal ganglia is
likely to form a shared underlying mechanism of both the dys-
tonia motor pathophysiology and fatigue.6,19 In particular, sero-
tonergic functioning in the basal ganglia might especially
contribute to both fatigue and dystonia.20 Decreased serotonin
transporter binding was observed in patients with PD, and was
even lower in those who had PD with fatigue.21 These findings
reinforce the hypothesis that a primary mechanism, intrinsic to
dystonia, may be responsible for the perception of fatigue in
patients with CD.
The severity of excessive daytime sleepiness and impaired
sleep quality was similar to the scores reported in other studies3
and was related even more to depressive and anxiety symptoms.
Pain, which was present in 77.3% of our patients, also appeared
to be significantly associated with impaired sleep quality, and
excessive daytime sleepiness was related to medication use. The
severity of dystonia and/or jerks/tremor was not associated with
excessive daytime sleepiness or an impaired sleep quality. A dif-
ferent approach to assessing the influence of motor symptoms
was used by Eichenseer et al., who examined patients before
and after BoNT treatment. Although BoNT significantly
improved the motor symptoms, there was no effect on the
excessive daytime sleepiness or sleep quality scores.9 Both
approaches suggest that the severity of motor symptoms does
not significantly contribute to excessive daytime sleepiness or an
impaired sleep quality. Along with the influence of depression
and pain, other factors, such as RLS, possibly also may con-
tribute. As described by Paus et al., the prevalence of RLS in
TABLE 5 Predictors of Decreased Health-related Quality of Life in Patients with Cervical Dystonia*
Domain Predictor(s) Adjusted R2 B° (SE) b P value
Physical functioning FSS 0.48 0.82 (0.16) 0.60 <0.01
TWSTRS pain 0.82 (0.40) 0.24 0.05
Social functioning BDI 0.37 1.88 (0.37) 0.62 <0.01
Role limitation-physical —
Role limitation-emotional BDI 0.48 2.80 (0.61) 0.52 <0.01
TWSTRS pain 2.50 (0.72) 0.39 <0.01
Mental health BDI 0.67 0.84 (0.24) 0.44 <0.01
ESS 0.81 (0.24) 0.39 <0.01
BAI 0.79 (0.23) 0.38 <0.01
FSS 0.24 (0.11) 0.26 0.03
Vitality BDI 0.49 1.03 (0.30) 0.45 <0.01
ESS 0.89 (0.32) 0.36 0.01
Pain TWSTRS pain 0.45 1.76 (0.46) 0.47 <0.01
FSS 0.56 (0.18) 0.37 <0.01
General health perception —
Expected health change —
R2, correlation coefﬁcient; B°, unstandardized coefﬁcient; SE, standard error; b, standardized regression coefﬁcient; FSS, Fatigue Severity
Scale; TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale; BDI, Beck Depression Inventory; ESS, Epsworth Sleepiness Scale; BAI,
Beck Anxiety Inventory.
*Clinical characteristics that were signiﬁcantly associated with decreased health-related quality of life were assessed with multiple linear
regression analysis after backward elimination. For variables that had a signiﬁcant inﬂuence, the adjusted R2, B° (with SE in parenthesis), and
b were calculated.
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CD was increased and was associated with an impaired sleep
quality.22 None of our participants had a medical history of
RLS, but it was not systematically investigated in our study.
Medications like benzodiazepines or GABAergic agents also
were related to higher excessive daytime sleepiness scores in our
patient cohort, but not to impaired sleep quality. Due to the
use of several types of medication, with different doses and vari-
able frequencies and ranging from sporadic to daily use, it was
not possible to perform a reliable correction for medication use.
However, the study by Eichenseer et al. did not identify an
influence of benzodiazepine use on sleep impairment in patients
with CD,9 suggesting that medication does not play a major
role in altered sleep in CD.
HR-QoL in patients with CD not only is influenced by psy-
chiatric comorbidity,5 but fatigue and excessive daytime sleepi-
ness also appeared to be significant contributors to a decreased
HR-QoL. The influence of tiredness on HR-QoL was previ-
ously described by Soeder et al., although they did not use a
CD-specific motor scale and thus could not exclude the influ-
ence of motor symptoms.4 In our study, the severity of dystonia
and of jerks and tremor was not associated with decreased HR-
QoL. The influence of fatigue and excessive daytime sleepiness
on HR-QoL highlights the need for systematic screening of
these symptoms in daily practice and the necessity of treating
possible contributing factors like depression and pain.
This study had several limitations. First, our results could
have been biased by the use of medication. Nine patients and 2
healthy controls used benzodiazepines, which could have
induced sedative effects and a reduced sleep quality.3 On the
other hand, the exclusion of patients using antidepressant medi-
cation also could have caused a selection bias by excluding
those with high depressive scores. In total, we did not include 8
patients who were using various antidepressants; and within the
different hospitals, several additional patients were not asked to
participate because of known medication use. Because depres-
sion appeared to be highly correlated with fatigue and excessive
daytime sleepiness, this could have influenced our results.
Therefore, the increased fatigue, excessive daytime sleepiness,
and sleep disturbance scores in our cohort may be underesti-
mated, emphasizing the need to screen for these symptoms in
daily practice. Second, in our study, we focused only on the
subjective sensations of fatigue, excessive daytime sleepiness, and
sleep quality. In future studies, objective measures to study fati-
gability or sleep quality, like electromyography or polysomnog-
raphy, would be helpful in understanding the underlying
pathophysiological mechanisms.
In conclusion, high rates of fatigue, excessive daytime
sleepiness, and sleep disturbances were detected in our study
among patients with DC. Independent from psychiatric
comorbidity, pain, and motor severity, fatigue appeared to be
a primary NMS. Sleep-related measures were highly associ-
ated with depression, anxiety, and pain, but not with motor
symptom severity. Importantly, only NMS significantly influ-
enced HR-QoL, whereas severity of motor symptoms had no
influence on any of the HR-QoL domains. Our results sug-
gest that fatigue, excessive daytime sleepiness, and a decreased
sleep quality are correlated with psychiatric comorbidity but
must be seen independently from motor symptoms and
require different treatment approaches. Future studies are war-
ranted to investigate pathophysiological mechanisms behind
fatigue and impaired sleep quality in patients with dystonia
and to assess whether targeted treatment of fatigue, excessive
daytime sleepiness, and sleep disturbances could improve
HR-QoL in patients with CD.
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